BRIEF-Astria, Kaken Ink Deal to Develop Navenibart for HAE in Japan

Reuters
Aug 06
BRIEF-Astria, Kaken Ink Deal to Develop Navenibart for HAE in Japan

Aug 6 (Reuters) - Astria Therapeutics Inc ATXS.O:

  • ASTRIA THERAPEUTICS ENTERS INTO LICENSING AGREEMENT WITH KAKEN PHARMACEUTICAL TO DEVELOP AND COMMERCIALIZE NAVENIBART FOR HAE IN JAPAN

  • ASTRIA THERAPEUTICS INC - UP TO $32 MILLION IN PAYMENTS PLUS ROYALTIES

  • ASTRIA THERAPEUTICS INC - EXPECTS CASH RUNWAY TO SUPPORT OPERATING PLAN INTO 2028

Source text: ID:nBw97ZYSBa

Further company coverage: ATXS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10